Status:
COMPLETED
Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking.
Lead Sponsor:
Philip Morris Products S.A.
Conditions:
Smoking
Abdominal Aortic Aneurysm
Eligibility:
All Genders
50+ years
Phase:
NA
Brief Summary
The purpose of this study was to evaluate the reduction of the Abdominal Aortic Aneurysm (AAA) annual growth rate in patients who switched from smoking cigarettes to using IQOS as compared to patients...
Detailed Description
This was a controlled, open-label, 3-arm parallel group, multi-center study in patients diagnosed with Abdominal Aortic Aneurysm (AAA) to evaluate the AAA annual growth rate in adult smokers randomize...
Eligibility Criteria
Inclusion
- General
- Patient diagnosed with AAA (infrarenal, fusiform type) with a current aortic maximum minor-axis diameter of 30 to ≤ 49 mm (in male patient) and 30 to ≤ 44 mm (in female patient).
- Patient has smoked on a daily basis (no brand restrictions) for at least 5 years prior to AAA diagnosis, based on self-reporting
- Patient is ready to comply with the study protocol (e.g., to use their assigned product/regimen during the course of the study)
- Inclusion criteria specific to patients screened for enrollment and randomization to the CC or IQOS arm:
- Patient has smoked on average at least 5 commercially available CC per day (no brand restriction) for the last 12 months, based on self-reporting. Intermittent attempts to quit smoking not exceeding 2 months or short-term interruption of smoking up to 10 days within the last 12 months will be allowed. Smoking status will be verified based on a urinary cotinine test (i.e., cotinine ≥ 200 ng/mL).
- Not intending to quit smoking within the next 6 months after having been advised to quit smoking.
- Inclusion Criteria specific to patients screened for enrollment into the SC arm:
- Patient had completely quit smoking and stopped the use of any other tobacco or nicotine-containing products within 6 months after AAA diagnosis, and is still abstinent at Screening and at Baseline. Smoking status will be verified based on a urinary cotinine test (i.e., cotinine \< 100 ng/mL).
Exclusion
- Patient is legally incompetent, physically or mentally incapable of giving consent.
- Patient is a current or former employee of the tobacco industry or their first-degree relatives (parent and child); patient is an employee of the investigational site or any other parties involved in the study or their first-degree relatives (parent and child).
- Patient has been previously screened or enrolled in this study or was enrolled in any clinical study within 3 months prior to the Screening Visit.
- Female patient who is pregnant or breast-feeding.
- Patient is ineligible as judged by the Investigator to participate in the study for any reason.
- Patient with acute severe cardiovascular events or respiratory diseases, within the last 3 months; with currently active cancer or history of cancer within the last 5 years; with dissecting aneurysm(s) of the aorta; with infrarenal pseudo-AAA (false AAA); with a diagnosis of COPD Stage 3 and 4 in the medical history; with a recent (within 1 year) or current history of alcohol or other substance abuse based on self-reporting.
- Patient with a diagnosis of concomitant genetic diseases such as but not limited to Marfan syndrome, Loeys-Dietz syndrome, Vascular Ehlers-Danlos syndrome, Turner syndrome, Polycystic kidney disease, Noonan syndrome, Alagile syndrome, Arterial tortuosity syndrome and Cutis laxa.
Key Trial Info
Start Date :
October 3 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 28 2023
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT03837704
Start Date
October 3 2018
End Date
August 28 2023
Last Update
August 26 2025
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Chiba-Nishi General Hospital
Matsudo, Chiba, Japan, 270-2251
2
Tokyo Bay Urayasu Ichikawa Medical Center
Urayasu, Chiba, Japan, 279-0001
3
Fujita General Hospital
Fujita, Fukushima, Japan, 969-1793
4
Kitakanto Cardiology Hospital
Shizukawa, Gunma, Japan, 377-0061